TNFSF11 and osteoporosis: In the following 50 years, a lot of novel pharmacological agents have been tested, only a very small part of them were finally approved to prevent and treat osteoporosis, most of which were anti-resorptive agents, including selective estrogen receptor modulators (SERMs), calcitonin, and monoclonal antibodies specific to RANKL (denosumab).